Silkworm pupa tablets tested to fight frailty after cancer surgery
NCT ID NCT06551675
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether silkworm pupa tablets can improve nutrition and reduce frailty in people who had surgery for stomach, colorectal, esophageal, or pancreatic cancer. 120 participants took the tablets for 3 months. Researchers measured weight, frailty, muscle mass, and quality of life to see if the supplement helps recovery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
120 people
The number who actually took part.
- Started
-
Aug 2024
- Finished
-
Oct 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Voluntarily participate in the clinical study, fully understand the study and sign the informed consent form (ICF); willing and able to follow and complete all trial procedures. * Gender unrestricted, age at the time of signing ICF: ≥18 years, ≤80 years. * Diagnosed with a malignant gastrointestinal tumor, including gastric cancer, colorectal cancer, esophageal cancer, and pancreatic cancer, and has undergone radical surgical resection. If necessary, perioperative systemic treatment has been completed by the time of screening. * At the time of screening, a nutritional risk score of ≥3 (based on the NRS 2002 nutritional risk screening tool) . * In good general condition, with an ECOG performance status score of ≤2. * Agree to provide peripheral blood, stool, and urine samples for biomarker analysis during the study period. Exclusion Criteria: * At the time of screening, presence of tumor recurrence or metastasis. * At the time of screening, presence of another active malignancy requiring concurrent treatment. * Expected survival of ≤3 months. * Unable to take oral nutrition, requiring enteral feeding tubes, or having malabsorption syndrome or any condition affecting gastrointestinal absorption; e.g., chronic diarrhea (watery stools; defecation frequency ≥5 times a day). * Patients who are planning a pregnancy, are pregnant, or are breastfeeding. * Allergic to any known components of the trial materials. * Presence of serious primary diseases of the heart, brain, lungs, liver, kidneys, endocrine, hematological, neurological, or other systems, or other acute or chronic diseases that could significantly affect treatment and prognosis. * Presence of other severe physical or mental illnesses or laboratory abnormalities that may increase the risk associated with participation in the study, or patients deemed unsuitable for participation by the researchers.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
Hangzhou, Zhejiang, 310000, China
-
Hangzhou Institute of Medicine Chinese Academy of Sciences
Hangzhou, China
-
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
-
The Second Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a personalized menu keep cancer patients stronger through chemotherapy?
- Gut bacteria may hold clues to why some cancer treatments work better
- Can a blood test before pancreatic surgery predict a dangerous leak?
- Burning the edges: a new way to stop colon polyps from coming back
- New chemo cocktail targets pancreatic cancer at every stage
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?